Alpha 2.0
Login Register
» Authors » Zhenpo Zhang

Zhenpo Zhang

Explore the profile of Zhenpo Zhang including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 5
Citations 0
Followers 0
Related Specialties
Pharmacology
Psychiatry
Psychology
Top 10 Co-Authors
Yankun Liang
Ling Su
Jingping Zheng
Yuting Wang
Lin Ma
Jiaxin He
Qimin Wu
Chufeng Din
Juanzhi Zhao
Haiyan Mai
Published In
Expert Opin Drug Saf
Ther Adv Drug Saf
Endocr Connect
Arch Womens Ment Health
Affiliations
Soon will be listed here.
Recent Articles
1.
Age-stratified analysis of adverse event signals for clarithromycin: a disproportionality analysis using the FDA Adverse Event Reporting System
Mai H, Zhang Z, Liang Y, Zheng J, Su L
Ther Adv Drug Saf . 2025 Jan; 16:20420986241311231. PMID: 39758824
Background: Clarithromycin is a widely used antibiotic, but its safety profile, particularly in different age groups, remains inadequately explored. Objectives: This study aims to characterize and illustrate the features of...
2.
Risk of congenital anomalies associated with psychotropic medications: a review of neonatal reports in the FDA adverse event reporting System (FAERS)
Zheng J, Zhang Z, Liang Y, Wu Q, Din C, Wang Y, et al.
Arch Womens Ment Health . 2024 Dec; PMID: 39710735
Purpose: This study investigates the potential association between commonly prescribed psychotropic medications, such as Atypical Antipsychotics (AAs), Selective Serotonin Reuptake Inhibitors (SSRIs), and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs), and congenital...
3.
Congenital anomalies associated with the use of cardiovascular drugs during pregnancy: a large-scale data analysis from the FAERS database
Zheng J, Ma L, Zhang Z, Liang Y, Din C, Wu Q, et al.
Expert Opin Drug Saf . 2024 Dec; 24(2):193-199. PMID: 39668461
Background: Cardiovascular drugs can cross the placenta during pregnancy, potentially exposing the fetus to teratogenic effects. However, ethical constraints on clinical trials with pregnant women limit safety data and result...
4.
Association of incretin-based therapies with hepatobiliary disorders among patients with type 2 diabetes: a case series from the FDA adverse event reporting system
Liang Y, Zhang Z, Zheng J, Wang Y, He J, Zhao J, et al.
Endocr Connect . 2024 Oct; 13(12). PMID: 39404734
Aim: Incretin therapies, including dipeptidyl peptidase-4 inhibitors (DPP-4is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs), are crucial for type 2 diabetes treatment. Evidence of their association with gallbladder, biliary diseases, and...
5.
Adverse events associated with azithromycin and clarithromycin in adults aged ≥65: a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database
Zhang Z, He J, Liang Y, Wang Y, Zheng J, Ma L, et al.
Expert Opin Drug Saf . 2024 Oct; :1-8. PMID: 39354723
Background: Azithromycin and clarithromycin are commonly used to treat community-acquired pneumonia in adults aged ≥ 65, such as mycoplasma pneumonia. This study aims to evaluate adverse events (AEs) associated with...